PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY

Neal D. Shore,E. David Crawford,Russell Z. Szmulewitz,Daniel P. Petrylak,Jeffrey Holzbeierlein,Arnauld Villers,Arun Azad,Antonio Alcaraz,Boris Alekseev,Taro Iguchi,Francisco Gómez Veiga,Brad Rosbrook,Benoit Baron,Gabriel P. Haas,Arnulf Stenzl,Andrew J. Armstrong

PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY

2020

Neal D. Shore
E. David Crawford
Russell Z. Szmulewitz
Daniel P. Petrylak
Jeffrey Holzbeierlein
Arnauld Villers
Arun Azad
Antonio Alcaraz
Boris Alekseev
Taro Iguchi
Francisco Gómez Veiga
Brad Rosbrook
Benoit Baron
Gabriel P. Haas
Arnulf Stenzl
Andrew J. Armstrong

INTRODUCTION AND OBJECTIVE:Enzalutamide (ENZA) + androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death in men with metastatic hormone-sensitive pros...

Keywords:

Androgen deprivation therapy
Urology
in patient
Prostate-specific antigen
Enzalutamide
Hormone sensitive prostate cancer
Docetaxel
Disease
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations